Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic agents for several skin conditions, Alzheimer's, Parkinson's, asthma and COPD. Signumâ€™s STM technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates.
7 Deer Park Drive
Monmouth Junction, NJ 08852
Signum Dermalogix receives $1.6m Phase II SBIR grant to develop atopic dermatitis therapeutics - Pharmaceutical Business Reviewitsoftware.pharmaceutical-business-review.com